**Abstracts**

**EP361/#717 DEVELOPING INFRASTRUCTURE FOR MOLECULAR PROFILING IN OVARIAN CANCER (DEMO)**

Elaine Leung, Gabriel Furingana, Lisa Bird, Marie-Lyne Alcaraz, Joo Ern Ang, Christine Parkinson, Merche Jimenez-Linan, Sue Freeman, Catherine Spencer, Julie Winning, Raji Ganesh, Sarah Williams, Kai Ren Ong, Parveen Abedin, William Boyle, Sudha Sundar, Janes Balega, James Brenton, University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, UK; University of Cambridge, Department of Oncology, Cambridge, UK; University of Birmingham, Library Services, Birmingham, UK; Addenbrooke’s Hospital, Cancer Services, Cambridge, UK; Addenbrooke’s Hospital, Pathology, Cambridge, UK; Addenbrooke’s Hospital, Radiology, Cambridge, UK; Pan-Birmingham Gynaecological Cancer Centre, Gynaecology, Birmingham, UK; University Hospitals Birmingham NHS Foundation Trust, Oncology, Birmingham, UK; Birmingham Women’s and Children’s NHS Foundation Trust, Pathology, Birmingham, UK; University Hospitals Birmingham NHS Foundation Trust, Clinical Genetics, Birmingham, UK; Birmingham Women’s and Children’s NHS Foundation Trust, Gynaecology, Birmingham, UK

10.1136/ijgc-2022-igcs.450

**Objectives** Poor patient understanding and biopsy quality could both reduce the number of successful molecular tests performed after the diagnosis of ovarian cancer. DEMO is a multi-centre quality improvement study that aims to improve the uptake and success rates of tumoural and germline molecular testing in ovarian cancer. The two lead sites that have vastly different patient demographics. One in 7 (15%) women diagnosed in Birmingham are non-Caucasian with high number of patients requiring interpreters for their consultations, whilst patients diagnosed in Cambridge are mostly Caucasian and fluent in English.

**Methods** The three components of DEMO include 1) the establishment of a patient advisory group to co-produce a multimedia, multilingual patient information package to support informed decision making, 2) the use of improvement methodology to analyse existing diagnostic pathways and 3) the development of a multidisciplinary consensus guideline to improve the current biopsy pathways for molecular profiling.

**Results** The first retrospective audit (n=75; January-August 2021) demonstrated high tumoural (BRCA or Homologous Repair Deficiency) testing failure rates of 25% (3/12) and 35% (11/31) of samples from image-guided biopsies and post-chemotherapy resections, respectively. A prospective audit pathway has been agreed to inform future practice. In addition, the first patients advisory group discussion in June 2022 will provide a qualitative narrative on patients’ perceptions on molecular testing and explore how patients would like such complex information conveyed to support patient information package development.

**Conclusions** Supporting informed decision making for all and establish auditable pathways are crucial for the implementation of molecular profiling to improve ovarian cancer care.

**EP363/#1122 CERVICAL CANCER AS A MARKER OF EXCLUSION TO HEALTH SERVICES AND SOCIAL VULNERABILITY**

Jurema Lima, Candice Santos, Carla Azevedo, Nathalia Ramalho, Leticia Sales, Paula Marina Santos, Andrea Pontes De Souza, Vanessa Lins, Caio Barros, Rodrigo Pinto, Vandre Carneiro, Fernanda Araujo, Maria Cecilia De Souza, Maria Julia De Mello, IMP/ DOR, Oncology, RECIFE, Brazil; IMP/ DOR, Oncology, RECIFE, Brazil; IMP/ DOR, Gynecologic, RECIFE, Brazil; IMP/ DOR, Oncology, RECIFE, Brazil; IMP/ DOR, Oncology, RECIFE, Brazil; IMP/ DOR, Surgical Oncology, RECIFE, Brazil; IMP/ DOR, Surgical Oncology, RECIFE, Brazil

10.1136/ijgc-2022-igcs.452

**Objectives** To evaluate care and primary and secondary prevention practices offered to cervical cancer patients and their families.

**Methods** Descriptive, observational, cross-sectional study. Carried out in the oncology of IMP (BRAZIL), using an adapted form, between 2020–2021. Socio-demographic data, cancer characteristics. Descriptive statistics were used to analyze the data.

**Results** Data were collected from 100 patients with CC aged 20 to 80 years. About the Pap smear, (89%) reported having heard about the preventive test and its function. 16% reported never having done it before diagnosis. 25% reported having performed the first exam between 15 and 24 years of age, while more than 50% stated that the first exam took place between 25 and 39 years of age. Regarding frequency, 35% of these patients reported annual exams. Regarding knowledge about the HPV vaccine, 78% claimed to have heard about their vaccine. Regarding knowledge of the age group to be vaccinated, 57% knew the target audience to be immunized, and among those who did not, the majority (80%) were unaware of HPV vaccination for boys. 76 women reported having relatives aged between 9 and 21 years. When asked about the vaccination status of these family members, 11% had not undergone immunization against HPV. The

**Int J Gynecol Cancer 2022;32(Suppl 3):A1–A274**

A201